Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
William A Denny & William R Wilson. (2000) Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opinion on Investigational Drugs 9:12, pages 2889-2901.
Read now
Read now
M. R. Horsman, L. E. Sampson, D. J. Chaplin & J. Overgaard. (1996) The in vivo interaction between flavone acetic acid and hyperthermia. International Journal of Hyperthermia 12:6, pages 779-789.
Read now
Read now
H.S. Edwards, J.C.M. Bremner & I.J. Stratford. (1991) Induction of Tumour Hypoxia by FAA and TNF: Interaction with Bioreductive Drugs. International Journal of Radiation Biology 60:1-2, pages 373-377.
Read now
Read now
J.C.M. Bremner, C.J.R. Counsell, H.S. Edwards, I.J. Stratford, G.E. Adams, A.B.W. Nethersell & P. Bedford. (1991) Monitoring Metabolic Responses after Induction of Hypoxia in the KHT Tumour Using 31P NMR Spectroscopy. International Journal of Radiation Biology 60:1-2, pages 363-367.
Read now
Read now
J.M. Brown. (1991) Targeting Bioreductive Drugs to Tumours: Is It Necessary to Manipulate Blood Flow. International Journal of Radiation Biology 60:1-2, pages 231-236.
Read now
Read now
Articles from other publishers (9)
Francesca Angileri, Vincent Roy, Geneviève Morrow, Jean Yves Scoazec, Nicolas Gadot, Diana Orejuela & Robert M. Tanguay. (2015) Molecular changes associated with chronic liver damage and neoplastic lesions in a murine model of hereditary tyrosinemia type 1. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1852:12, pages 2603-2617.
Crossref
Crossref
Etresia van Dyk & Pieter J. Pretorius. (2011) Point mutation instability (PIN) mutator phenotype as model for true back mutations seen in hereditary tyrosinemia type 1 – a hypothesis. Journal of Inherited Metabolic Disease 35:3, pages 407-411.
Crossref
Crossref
Xiao Qiu, Hongli Zhao, Ronghua Yu, Jiufeng Zhang & Minbo Lan. (2011)
Novel ferrocenyl nitroxide nanoparticles as electron paramagnetic resonance oximetry probes
in vitro
and
in vivo
. Nanomedicine 6:2, pages 225-231.
Crossref
Crossref
Rumi Murata, Dietmar W. Siemann, Jens Overgaard & Michael R. Horsman. (2001) Improved Tumor Response by Combining Radiation and the Vascular-Damaging Drug 5,6-Dimethylxanthenone-4-acetic Acid. Radiation Research 156:5, pages 503-509.
Crossref
Crossref
K. Indira PriyadarsiniMadeleine F. DennisMatthew A. NaylorMichael R. L. StratfordPeter Wardman. (1996)
Free Radical Intermediates in the Reduction of Quinoxaline
N
-Oxide Antitumor Drugs: Redox and Prototropic Reactions
. Journal of the American Chemical Society 118:24, pages 5648-5654.
Crossref
Crossref
Stephen Cliffe, Maryann L. Taylor, Michael Rutland, Bruce C. Baguley, Richard P. Hill & William R. Wilson. (1994) Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. International Journal of Radiation Oncology*Biology*Physics 29:2, pages 373-377.
Crossref
Crossref
Gerald E. Adams & Ian J. Stratford. (1994) Bioreductive drugs for cancer therapy: The search for tumor specificity. International Journal of Radiation Oncology*Biology*Physics 29:2, pages 231-238.
Crossref
Crossref
Jane C. M. Bremner. (1993) Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference toin vivo methods of evaluation. Cancer and Metastasis Reviews 12:2, pages 177-193.
Crossref
Crossref
William A. Denny & William R. Wilson. (1993) Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer and Metastasis Reviews 12:2, pages 135-151.
Crossref
Crossref